| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Tetrabutylammonium perrhenate does not have a specific biological target as it is a chemical reagent used in organic synthesis and radiopharmaceutical development. Its primary function is as a source of the perrhenate anion for various chemical reactions. In radiopharmaceutical applications, the perrhenate moiety can be used to incorporate radioactive rhenium isotopes for diagnostic imaging or therapy. The compound's lipophilic cation facilitates its solubility in organic solvents.
|
|---|---|
| ln Vitro |
In research pertaining to life sciences, tetrabutylammonium perrhenate is a biochemical reagent that can be utilized as an organic substance or biological material.
In vitro activity is not assessed for this compound in a pharmacological context, as it is used as a chemical reagent and catalyst. Its reactivity is characterized by its ability to transfer the perrhenate anion in various chemical transformations. The compound is used in the synthesis of rhenium complexes with o-phenylenediamine and o-aminobenzenethiol, and for perrhenate salt formation with nickel porphyrins. |
| ln Vivo |
In vivo biological activity is not applicable for this compound, as it is a chemical reagent rather than a therapeutic agent. However, its potential use in radiopharmaceuticals involves the incorporation of radioactive rhenium isotopes for diagnostic or therapeutic applications. The compound itself is not administered as a drug but may be used in the preparation of radiopharmaceuticals for nuclear medicine.
|
| Enzyme Assay |
Non-cellular experiments for this compound typically involve its use as a catalyst or reagent in organic synthesis. A typical protocol includes dissolving the compound in an organic solvent and adding it to a reaction mixture containing substrates for rhenium-mediated transformations. The compound can also be used as a starting material for the synthesis of rhenium complexes. Analytical methods such as NMR and mass spectrometry are used to characterize products.
|
| Cell Assay |
Cell-based assays are not applicable for this compound, as it is a chemical reagent used in synthesis rather than a pharmacological agent. It is not tested in cell culture models for biological activity. The compound is used exclusively in chemical research and radiopharmaceutical development. Researchers should handle this compound with appropriate safety precautions.
|
| Animal Protocol |
In vivo animal studies are not performed with this compound in a therapeutic context. Its applications are confined to chemical synthesis and radiopharmaceutical development. No efficacy or safety studies in animal models are available for the compound itself. The compound is not intended for direct administration to humans or animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not characterized for this compound, as it is a chemical reagent rather than a therapeutic agent. Its molecular weight is 492.67 g/mol, and it is a solid at room temperature. The compound is soluble in organic solvents. No data on absorption, distribution, metabolism, or excretion are available.
|
| Toxicity/Toxicokinetics |
Toxicological data for this compound are limited. Rhenium compounds can be toxic and should be handled with appropriate safety precautions. The compound is stable under recommended storage conditions. No carcinogenic or reproductive toxicity data are available. Researchers should consult the safety data sheet for specific hazard information and handling guidelines. The compound is not intended for human use.
|
| Additional Infomation |
Tetrabutylammonium perrhenate is a quaternary ammonium salt used as a catalyst and reagent in organic synthesis. Its CAS number is 16385-59-4. The compound is available with a purity of >98% from various suppliers. It is used in the synthesis of rhenium complexes and as a model compound for diagnostic radiopharmaceuticals. The compound is not approved for therapeutic use but is an important tool for chemical research. It should be stored at room temperature in a cool, dry place.
|
| Molecular Formula |
C16H36NO4RE
|
|---|---|
| Molecular Weight |
492.67
|
| Exact Mass |
493.22
|
| CAS # |
16385-59-4
|
| PubChem CID |
11123851
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.528
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
22
|
| Complexity |
212
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC[N+](CCCC)(CCCC)CCCC.[O-][Re](=O)(=O)=O
|
| InChi Key |
MTTXKKTWRLXAKW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H36N.4O.Re/c1-5-9-13-17(14-10-6-2,15-11-7-3)16-12-8-4;;;;;/h5-16H2,1-4H3;;;;;/q+1;;;;-1;
|
| Chemical Name |
oxido(trioxo)rhenium;tetrabutylazanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0298 mL | 10.1488 mL | 20.2976 mL | |
| 5 mM | 0.4060 mL | 2.0298 mL | 4.0595 mL | |
| 10 mM | 0.2030 mL | 1.0149 mL | 2.0298 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
